Back to news

Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application

Business Wire•15/11/2026•07:00 ET
1

Key Highlights

  • ➤FDA rejects ivonescimab BLA in present form over missing statistically significant overall survival improvement
  • ➤HARMONi met its progression-free survival endpoint but failed to establish statistically significant overall survival
  • ➤FDA determined progression-free survival benefit alone did not support a positive benefit-risk profile
  • ➤Summit continues Phase III development across NSCLC, colorectal, urothelial, and renal cell cancers
  • ➤Ivonescimab received initial marketing authorization in China in May 2024

Expert Statements

Maky Zanganeh, President and Co-Chief Executive Officer of Summit Therapeutics

“As a cancer survivor, I understand firsthand how important it is for patients to have access to multiple treatment options, particularly when they are facing diseases with significant unmet medical needs.”

Maky Zanganeh, President and Co-Chief Executive Officer of Summit Therapeutics

“Behind every diagnosis is a person, a family, and a community hoping for more time, more possibilities, and a better future.”

Maky Zanganeh, President and Co-Chief Executive Officer of Summit Therapeutics

“I know that hope is not simply an emotion; it is the possibility that another treatment, another scientific breakthrough, or another therapeutic option may make a meaningful difference in someone’s life.”

Maky Zanganeh, President and Co-Chief Executive Officer of Summit Therapeutics

“Every additional treatment option matters.”

Maky Zanganeh, President and Co-Chief Executive Officer of Summit Therapeutics

“It represents another opportunity for patients and their families, especially those who have exhausted existing therapies or have limited alternatives.”

Maky Zanganeh, President and Co-Chief Executive Officer of Summit Therapeutics

“Our responsibility as an industry is to continue advancing science, challenging conventional thinking, and bringing innovative medicines to patients in need.”

Maky Zanganeh, President and Co-Chief Executive Officer of Summit Therapeutics

“For me, our mission is deeply personal to bring our innovative medicine to patients who may benefit most.”

Robert W. Duggan, Chairman and Co-Chief Executive Officer of Summit Therapeutics

“We are disappointed for patients and their families awaiting additional treatment options in this setting.”

Robert W. Duggan, Chairman and Co-Chief Executive Officer of Summit Therapeutics

“We chose to pursue an ivonescimab regimen here based on the opportunity to provide another treatment option to help patients in need.”

Robert W. Duggan, Chairman and Co-Chief Executive Officer of Summit Therapeutics

“In doing so, we believe the global HARMONi study provided the basis for a treatment option that these patients needed.”

Robert W. Duggan, Chairman and Co-Chief Executive Officer of Summit Therapeutics

“With five positive Phase III studies between Summit and Akeso, nothing changes with respect to our ever-growing belief in the opportunity for ivonescimab and our determination to advance ivonescimab’s development.”

Robert W. Duggan, Chairman and Co-Chief Executive Officer of Summit Therapeutics

“Our mission remains to improve outcomes for patients facing significant unmet needs, which is work worth doing, and we will continue through our expansive clinical development program.”

Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application

Complete Response Letter Received from FDA for BLA Application Based on HARMONi Study

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in